Regulatory news​

Observe Medical ASA has today, May 26, 2023, held the Annual General Meeting. All resolutions were made in accordance with the board's and the nomination committee's proposals. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com. For further information, please contact:   Rune Nystad, CEO Observe Medical Mobile:…

Oslo, 26 May 2023 – Observe Medical ASA (the "Company" or "Observe Medical") has received initial orders from distributors for delivery of UnoMeter™ products and is expecting to ship the first units to customers in June. The total value of these initial orders is NOK 8.2 million. The distributors that have signed the orders have…

Oslo, May 5, 2023 – Observe Medical ASA (OBSRV): The annual general meeting of Observe Medical ASA will be held on Friday, May 26, 2023, at 10:00 (CET). The annual general meeting will be held at Dronning Eufemias gate 16, 0191 Oslo for those attending in person. The Notice of the Annual General Meeting is attached.…

Oslo, 28 April 2023 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Company has published its Annual Report for 2022. The Annual Report was approved by the Board of Directors on 27 April 2023. “In 2022, Observe Medical explored several paths to broaden our product portfolio and secure production capacity.…

Oslo, March 23, 2023 – Observe Medical ASA ("Observe Medical" or "the Company") has entered into loan agreements for its short term financing needs. Further to the stock exchange announcement on 14 December 2022, the Company has entered into loan agreements where the lenders have committed to an amount of NOK 10 million. The Company…

Observe Medical ASA: Fourth quarter 2022 results Oslo, 17 February 2023 – Observe Medical ASA (“the Company” or “Observe Medical”) today releases its results for the fourth quarter of  2022. "The year 2022 has been a transformational year for Observe Medical. Building on the growth initiatives seen earlier in the year, we signed two exclusivity…

Oslo, 14 December 2022 – The Nordic medtech company Observe Medical ASA ("Observe Medical" or "the Company") is planning to issue a NOK 30-50 million bond loan in the first quarter of 2023, which is expected to be followed by a NOK 100-150 million equity issue around mid-year 2023. It is contemplated that the bond…

Observe Medical ASA (the "Company") has on November 11, 2022, granted 1,000,000 share options in the Company to the group CEO, Rune Nystad. The options have been granted with an exercise price of NOK 4.5 per option share. The options will west in three tranches, whereby each tranche comprising 1/3 of the options will vest…

Oslo, 3 November 2022 – Observe Medical ASA (“the Company” or “Observe Medical”) today release its results for the third quarter of 2022. "In October, we announced that Observe Medical had entered into an exclusive agreement with the intention to acquire Convatec’s Unometer urine measurement portfolio, consisting of several market-leading brand names such as Unometer™…

Observe Medical aims for a transformative acquisition to become the leading urine measurement system provider Oslo, 21 October 2022 – Observe Medical ASA ("Observe Medical" or "the Company" and together with its subsidiary "the Group") has entered into an exclusive agreement with the intention to acquire the rights to own, produce and sell an extensive…

Oslo, 25 August 2022 – Observe Medical ASA (“the Company” or “Observe Medical”) today release its results for the second quarter and first half year of  2022. Following the acquisition of Biim Ultrasound in March 2022 and corresponding high corporate activity, Observe Medical has worked to integrate and extract operational synergies across the company and…

Oslo, 22 August 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), will release its second quarter and first half year 2022 results on Thursday, 25 August 2022. The presentation and report will be made available on NewsWeb and the Company’s website at 07:00 CET on the same day. Rune Nystad, CEO, and…

Observe Medical ASA has today, June 3, 2022, held the Annual General Meeting. All resolutions were made in accordance with the board's and the nomination committee's proposals. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com. For further information, please contact:   Rune Nystad, CEO Observe Medical Mobile:…

Oslo, 3 June 2022 – Observe Medical ASA (OSE: OBSRV) (“the Company” or “Observe Medical”) today releases its first quarter results for 2022. Observe Medical has made progress across its medtech platform during the quarter, preparing and strengthening it for growth. The Company has also streamlined the organization and other operational synergies following the acquisition…

Oslo, May 13, 2022 – Observe Medical ASA (OSE:OBSRV): The annual general meeting of Observe Medical ASA will be held on Friday, June 3 2022 at 10:00 (CET). The annual general meeting will be held at Haakon VIIs gate 2, 0161 Oslo for those attending in person and via Lumi for those attending digitally. Voting…

Oslo, 29 April 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Company has published its Annual Report for 2021, which was approved by the board of directors on 28 April 2022. "It has been a transformational start to 2022, so I would like to take this opportunity to focus…

Oslo, 29 March 2022 – Observe Medical ASA (“the Company” or “Observe Medical”) today releases a combined business update and interim financial results for the fourth quarter and full year 2021. Observe Medical can also report that 202 out of 260 Biim ultrasound probes have been successfully shipped. Another 58 Biim probes will be delivered…

The Board of Directors has today appointed Rune Nystad as Chief Executive Officer (CEO) of Observe Medical ASA  (the “Company” or “Observe Medical”), a Nordic medtech company with global reach. He succeeds Björn Larsson, who has headed the Company since 2019. Rune Nystad was previously the CEO of Biim Ultrasound, a company recently acquired by…

Oslo, 10 March 2022: Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company") on 8 March 2022 regarding the Company's completion of the acquisition of Biim Ultrasound AS and the issuance of 8,171,913 new shares in the Company as partial consideration to the sellers of Biim Ultrasound AS (the "Consideration…

Oslo, 8 March 2022: Observe Medical ASA (OSE: OBSRV) (the "Company" or Observe Medical") is excited to announce the completion of the acquisition of Biim Ultrasound AS ("Biim Ultrasound"), an international medical ultrasound technology company, adding another innovative product that improves patient welfare and outcome and that promotes positive health economics to its portfolio. With…

7 March 2022: Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company ") on 24 February 2022, regarding the final result of the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per Offer Share (the "Rights Issue"). The…

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 21 February 2022, regarding the exercise of subscription rights in the rights issue by certain primary insiders and a close associate of a primary insider, and today, on 24 February 2022 regarding the final results of the rights issue…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per offer share (the "Rights Issue"). Thomas Grunfeld,…

Mandatory disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act by Navamedic ASA. Reference is made to the previous stock exchange announcements from Observe Medical ASA (the "Company") announcing a fully underwritten rights issue of 25,714,286 new shares in the Company, raising gross proceeds of approximately NOK 180 million (the "Rights Issue"). In…

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of…

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per offer share (the "Rights Issue"). Thomas Grunfeld,…

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of…

Oslo, February 21, 2022 – Observe Medical ASA (OSE: OBSRV) today announces a new order for Sippi systems, from our distributor in Poland, Skamex.    Observe Medical ASA (the "Company") has today, on 21 February 2022, received an order for  30 Sippi® Base units and 300 Sippi® Disposable units from Skamex. The total order value…

Mandatory disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act by TopRidge Pharma (Ireland) Limited ("TopRidge Pharma"). Reference is made to the previous stock exchange announcements from Observe Medical ASA (the "Company") announcing a fully underwritten rights issue of 25,714,286 new shares in the Company, raising gross proceeds of approximately NOK 180 million…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") earlier today, on 9 February 2022, regarding the commencement of the subscription period in the rights issue (the "Rights Issue"). Please see the attached notifications of trade for information regarding the primary insiders' and their close associates' receipt of subscription…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

Oslo, February 7, 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter (in Norwegian) in relation to the fully underwritten rights issue in…

Issuer name: Observe Medical ASA Ex.date: 7 February 2022 Type of corporate action: Rights issue This information is published in accordance with the requirements of the Continuing Obligations.

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 14 January 2022 regarding a proposed fully underwritten rights issue in the Company (the "Rights Issue"). The extraordinary general meeting of the Company has today, on 4 February 2022, approved the Rights Issue and the authorisation to the board…

Reference is made to the key information relating to the preferential rights issue published by Observe Medical ASA (the "Company") on 14 January 2022. Please see below for updated key information relating to the preferential rights issue to be carried out by the Company: Date on which the terms and conditions of the preferential rights…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

Oslo, 2 February 2022: In connection with the extraordinary general meeting of Observe Medical ASA (the "Company") to be held on 4 February 2022 (the "EGM"), Terje Bakken, chairman of the board of directors of the Company, has as at the close of trading on the Oslo Stock Exchange on 2 February 2022, received proxies…

· Observe Medical will develop and commercialize proprietary, innovative medtech products to the global market · International distributor and partner network with a Nordic direct sales organization · The agreement is set to accelerate the global commercial roll-out of the combined portfolio, including Sippi® US market launch and the entry of Biim in Europe Oslo,…

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") earlier today, on 14 January 2022, regarding the resolution by the Company's board of directors to propose that the Company carries out a share capital increase, by way of a fully underwritten rights issue, to raise gross proceeds of NOK…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END…

16 November 2021: The board of directors of Observe Medical ASA (the "Company") has resolved to grant 120,000 share options in the Company to the group CFO, Per Arne Nygård. Per Arne Nygård was engaged as interim CFO of the group as an consultant on 10 December 2019, and was permanently employed as CFO of…

Oslo, November, 3rd, 2021 – Observe Medical ASA (OSE: OBSRV) today released its financial results and presentation of the third quarter of 2021. The Company reports strong revenue growth for the Nordic portfolio, continued progress in the commercialization and go-to-market execution for Sippi® including an update on preparations for US market entry. CEO of Observe Medical,…

Observe Medical ASA invites you to a presentation of the third quarter 2021. The presentation will take place at Felix Konferansesenter in Oslo on Wednesday, November 3rd. The event will start at 08.30 CET and will be webcasted live on www.observemedical.com – Investor relations and at the following link: https://channel.royalcast.com/landingpage/hegnarmedia/20211103_5/ Representatives from the Company will…

FINANCIAL YEAR 2021 03.11.2021 – Quarterly Presentation – Q3 17.02.2022 – Quarterly Presentation – Q4 29.04.2022 – Annual Report 02.06.2022 – Annual General Meeting FINANCIAL YEAR 2022 12.05.2022 – Quarterly Presentation – Q1 25.08.2022 – Second quarter and Half-year Report 03.11.2022 – Quarterly Report – Q3 This information is published pursuant to the requirements set out…

Oslo, August 20[th], 2021 – Observe Medical ASA (OSE: OBSRV) today released its financial results and presentation of the second quarter and first half-year of 2021, reporting continuous progress in the go-to-market execution for Sippi®, a unique and proprietary solution for digital, automated urine monitoring. “We have a sharp focus on continuous roll-out of Sippi®,…